Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes.
Yang X, Tamez H, Lai C, Ho K, Cutlip D.
Catheter Cardiovasc Interv. 2017 Apr;89(5):849-856. doi: 10.1002/ccd.26688. Epub 2016 Aug 18.
Effects of Metoprolol on Periprocedural Myocardial Infarction After Percutaneous Coronary Intervention (Type 4a MI): An Inverse Probability of Treatment Weighting Analysis.
Li D, Li Y, Lin M, Zhang W, Fu G, Chen Z, Jin C, Zhang W.
Front Cardiovasc Med. 2021 Nov 23;8:746988. doi: 10.3389/fcvm.2021.746988. eCollection 2021.
The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction - from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC).
Mair J, Jaffe A, Lindahl B, Mills N, Möckel M, Cullen L, Giannitsis E, Hammarsten O, Huber K, Krychtiuk K, Mueller C, Thygesen K.
Biomarkers. 2022 Jul;27(5):407-417. doi: 10.1080/1354750X.2022.2055792. Epub 2022 May 26.
Soluble fms-like tyrosine kinase-1 (sFLT-1) predicts post-percutaneous coronary intervention (PCI) myocardial infarction (MI type 4a).
Searle J, Slagman A, Gwosc S, Vollert JO, Holert F, Müller C, Muller R, Möckel M.
Biomarkers. 2012 Dec;17(8):730-7. doi: 10.3109/1354750X.2012.725428. Epub 2012 Oct 3.
Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
Lattuca B, Mazeau C, Cayla G, Ducrocq G, Guedeney P, Laredo M, Dumaine R, El Kasty M, Kala P, Nejjari M, Hlinomaz O, Morel O, Varenne O, Leclercq F, Payot L, Spaulding C, Beygui F, Rangé G, Motovska Z, Portal JJ, Vicaut E, Collet JP, Montalescot G, Silvain J; ALPHEUS Investigators.
JACC Cardiovasc Interv. 2024 Feb 12;17(3):359-370. doi: 10.1016/j.jcin.2023.12.011.
[Clinical implications of the fourth universal definition of myocardial infarction].
Eckner D, Pauschinger M, Ademaj F, Martinovic K.
Herz. 2020 Sep;45(6):520-527. doi: 10.1007/s00059-020-04948-6.
The universal classification is an independent predictor of long-term outcomes in acute myocardial infarction.
Gonzalez MA, Eilen DJ, Marzouq RA, Porterfield CP, Hazarika S, Nasir S, Patel AA, Gonzalez Kde J, Burris MB, Prieto-Gonzalez M, Rose JD, Cascio WE; Multidisciplinary Atherosclerosis Prevention Program.
Cardiovasc Revasc Med. 2011 Jan-Feb;12(1):35-40. doi: 10.1016/j.carrev.2009.11.006. Epub 2010 Oct 20.
Reliability using the universal classification of acute myocardial infarction compared to ST-segment classification.
Gonzalez MA, Marzouq RA, Nasir S, Hazarika S, Burris MB, Saunders C, Porterfield CP, Eilen DJ, Gonzalez Kde J, Patel AA, Prieto-Gonzalez M, Graham T 3rd, Awadallah S, Rose JD, Cascio WE; Multidisciplinary Atherosclerosis Prevention Program (MAPP).
Cardiovasc Revasc Med. 2011 Jul-Aug;12(4):210-6. doi: 10.1016/j.carrev.2010.06.002. Epub 2011 Jan 26.
[The periprocedural myocardial infarction and probability of the developing of the contrast-induced acute kidneys injury in clinical practice. Case report].
Dmitrieva OA, Mironova OY, Sivakova OA, Denisova AR, Solnceva TD, Fomin VV.
Ter Arkh. 2021 Apr 15;93(4):482-486. doi: 10.26442/00403660.2021.04.200686.
Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial.
Huang Z, Zhuang X, Zhang S, Huang Y, Yuan L, Lin A, Tang L, Xiong Z, Christopher O, Chen Y, Wu B, Ling Y, Li S, Jie Q, Xiong L, Qian X, Liao X, Liu J.
BMJ Open. 2023 Jul 11;13(7):e072541. doi: 10.1136/bmjopen-2023-072541.
